Diphtheria vaccine


Diphtheria vaccine is a vaccine against Corynebacterium diphtheriae, the bacterium that causes diphtheria. Its use has resulted in a more than 90% decrease in number of cases globally between 1980 and 2000. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after which it is about 95% effective during childhood. Three further doses are recommended during childhood. It is unclear if further doses later in life are needed.
The diphtheria vaccine is very safe. Significant side effects are rare. Pain may occur at the injection site. A bump may form at the site of injection that lasts a few weeks. The vaccine is safe in both pregnancy and among those who have a poor immune function.
The diphtheria vaccine is delivered in several combinations. Some combinations include tetanus vaccine, others comes with the tetanus and pertussis vaccines, and still others include additional vaccines such as Hib vaccine, hepatitis B vaccine, or inactivated polio vaccine. The World Health Organization has recommended its use since 1974. About 84% of the world population is vaccinated. It is given as an intramuscular injection. The vaccine needs to be kept cold but not frozen.
The diphtheria vaccine was developed in 1923. It is on the World Health Organization's List of Essential Medicines.

Effectiveness

About 95% of people vaccinated develop immunity, and vaccination against diphtheria has resulted in a more than 90% decrease in number of cases globally between 1980 and 2000. About 86% of the world population was vaccinated as of 2016.

Side effects

Severe side effects from diphtheria toxoid are rare. Pain may occur at the injection site. A bump may form at the site of injection that lasts a few weeks. The vaccine is safe during pregnancy and among those who have a poor immune function. DTP vaccines may cause additional adverse effects such as fever, irritability, drowsiness, loss of appetite, and, in 6–13% of vaccine recipients, vomiting. Severe adverse effects of DTP vaccines include fever over 40.5 °C/104.9 °F, febrile seizures, and hypotonic-hyporesponsive episodes. Side effects of DTaP vaccines are similar but less frequent. Tetanus toxoid containing vaccines may cause brachial neuritis at a rate of 0.5 to 1 case per 100,000 toxoid recipients.

Recommendations

The World Health Organization has recommended vaccination against diphtheria since 1974. The first dose is recommended at six weeks of age with two additional doses four weeks apart, after receiving these three doses about 95% of people are immune. Three further doses are recommended during childhood. Booster doses every ten years are no longer recommended if this vaccination scheme of 3 doses + 3 booster doses is followed. Injection of 3 doses + 1 booster dose, provides immunity for 25 years after the last dose. If only three initial doses are given, booster doses are needed to ensure continuing protection.